The purchase of Alere's Series B convertible perpetual preferred stock at $402 per share is in connection to Abbott's $5.3 billion acquisition of Alere.
Quidel said that the purchases, expected to close in September, would give it an expanded portfolio of rapid diagnostic capabilities in critical care.
About 63 million votes were in favor of the deal, representing more than 72.5 percent of all outstanding Alere shares as of the May 31 record date.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
The analyzer, part of Abbott's Alinity portfolio, is designed to streamline clinical workflows for high-volume laboratories and hospital systems.
Sales for its cardiometabolic tests dropped sharply, while sales for its flu tests soared and its consumer diagnostics sales were flat.
As the diagnostics industry launches high-throughput systems to large labs for HbA1c testing, clinicians also see a market need for point-of-care testing.
The firm's Q4 global influenza sales were up 60 percent year over year, and in 2016 its global infectious disease business achieved double-digit sales growth.
The firm also reported that both preliminary 2016 revenues and preliminary Q4 revenues would be down 3 percent.